JAGSONPAL PHARMACEUTICALS
JAGSNPHARM · General/Diversified · NSE
₹197
Current Market Price
Fair Value (DCF)
₹184
Margin of Safety
-6.1%
Updated 1d ago
YieldIQ Score
61/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
71%
ROE
—
Debt/Equity
0.03
WACC
11.1%
Market Cap
₹1,319 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
28.1%
Return on capital employed
EV / EBITDA
19.8×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
73.8×
EBIT covers interest
Current Ratio
6.22×
Short-term liquidity
Asset Turnover
0.97×
Revenue per ₹ of assets
Revenue CAGR (3Y)
7.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹196.5
Bear case
₹99.85
MoS -96.8%
Base case
₹184.45
MoS -6.5%
Bull case
₹212.4
MoS +7.5%
Ratio Trends
JAGSNPHARM · last 7 annual periods
ROE
23.1%
ROCE
31.6%
Operating Margin
—
Debt / Equity
0.04×
PE
72.8×
EV / EBITDA
53.5×
Historical Financials
JAGSNPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹188 Cr | ₹226 Cr | ₹55.5 Cr | ₹43.5 Cr | ₹269 Cr | +9.3% |
| EBITDA | — | ₹28.4 Cr | ₹36.3 Cr | ₹32.3 Cr | ₹78.8 Cr | +29.0% |
| EBIT | ₹22.4 Cr | ₹27.6 Cr | ₹7.5 Cr | ₹4.8 Cr | — | -32.1% |
| PAT | ₹17.1 Cr | ₹19.6 Cr | ₹5.6 Cr | ₹3.5 Cr | ₹55.4 Cr | +34.2% |
| EPS (diluted) | ₹6.51 | ₹7.48 | ₹2.14 | ₹1.31 | — | -33.0% |
| CFO | ₹28.2 Cr | ₹5.6 Cr | ₹40.1 Cr | ₹35.2 Cr | ₹55.3 Cr | +18.3% |
| CapEx | — | — | — | — | ₹-0.3 Cr | — |
| FCF | — | — | — | — | ₹55.0 Cr | +0.0% |
| Total Assets | — | ₹164 Cr | ₹195 Cr | ₹217 Cr | ₹278 Cr | +14.1% |
| Total Debt | — | — | ₹0.0 Cr | ₹0.0 Cr | ₹9.2 Cr | — |
| Shareholders' Equity | — | — | ₹159 Cr | ₹187 Cr | ₹240 Cr | +10.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JAGSNPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SAKAR SAKAR | — | — | Pending | 6.1% | — |
| SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
| BETA BETA | — | — | Pending | 21.5% | — |
| VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
| BAJAJHCARE BAJAJHCARE | — | — | Pending | 8.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for JAGSNPHARM in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JAGSNPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JAGSNPHARM →
Compare
Head-to-head with peers
Compare JAGSNPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JAGSNPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.